Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients infected with Clonorchis sinensis: a single-centre, open-label, randomised controlled study

The National Institute of Parasitic Diseases (China)0 个研究点目标入组 120 人开始时间: 2011年5月19日最近更新: 2016年10月17日

适应症

试验速览

暂无简介。

•Current inclusion criteria as of 14/08/2012:
•Eligible patients are residents of Hunan province aged 15 to 65 years who have Clonorchis sinensis infections, both sexes.
•Previous inclusion criteria until 14/08/2012:
•Eligible patients are residents of Guangdong province aged 2 years and above who had Clonorchis sinensis infections, both sexes

•1. Pregnant or lactating women
•2. Presence of any abnormal medical condition, such as heart disease, high blood pressure, severe malnutrition, severe liver and kidney disease, psychiatric and neurologic disorders
•3. Use of praziquantel , tribendimidine, albendazole and mebendazole or any anthelminthic treatment within the past month
•4. Enrolled in any other clinical investigation during the study

发起方

The National Institute of Parasitic Diseases (China)